News
ACHV
4.540
+0.89%
0.040
Weekly Report: what happened at ACHV last week (0415-0419)?
Weekly Report · 2d ago
JonesTrading Initiates Coverage of Achieve Life Sciences (ACHV) with Buy Recommendation
NASDAQ · 6d ago
Jones starts Achieve Life Sciences at buy, cites market opportunity
Seeking Alpha · 6d ago
Achieve Life Sciences Price Target Announced at $20.00/Share by JonesTrading
Dow Jones · 04/17 14:24
Achieve Life Sciences Initiated at Buy by JonesTrading
Dow Jones · 04/17 14:24
ACHIEVE LIFE SCIENCES INC <ACHV.O>: JONESTRADING INITIATES COVERAGE WITH BUY RATING; TARGET PRICE $20
Reuters · 04/17 04:55
Achieve Life Sciences: A Strong Buy for Tobacco Cessation Market Penetration
TipRanks · 04/16 20:25
Weekly Report: what happened at ACHV last week (0408-0412)?
Weekly Report · 04/15 09:33
Weekly Report: what happened at ACHV last week (0401-0405)?
Weekly Report · 04/08 09:35
Achieve Life Sciences: An Excellent Drug Addressing A Large Market Could Drive 5x Returns
A Achieve Life Sciences is working to commercialize the smoking cessation drug Cytisinicline. The drug has shown promising results in clinical trials and has the potential to address a large market. The company is expected to be sold to a larger entity in 2025, with potential returns of 4-9x for investors.
Seeking Alpha · 04/04 10:30
Achieve Life Sciences Price Target Maintained With a $18.00/Share by Oppenheimer
Dow Jones · 04/01 13:24
Oppenheimer Reiterates Outperform on Achieve Life Sciences, Maintains $18 Price Target
Benzinga · 04/01 13:14
Analysts Offer Insights on Healthcare Companies: Forian (FORA), Achieve Life Sciences (ACHV) and P3 Health Partners (PIII)
TipRanks · 04/01 13:00
Analysts Offer Insights on Healthcare Companies: Achieve Life Sciences (ACHV) and Phathom Pharmaceuticals (PHAT)
TipRanks · 04/01 10:50
Weekly Report: what happened at ACHV last week (0325-0329)?
Weekly Report · 04/01 09:35
ACHV Stock Earnings: Achieve Life Sciences Beats EPS for Q4 2023
Achieve Life Sciences reported earnings per share of -26 cents for the fourth quarter of 2023. The company did not report any revenue for the quarter. Achieve Life Sciences was above the analyst estimate for EPS of -31 cents. The company just reported results for fourth quarter.
Investorplace · 03/29 00:53
Achieve Life Sciences Inc reports results for the quarter ended in December - Earnings Summary
Achieve Life Sciences Inc reports results for the quarter ended in December. The company reported a quarterly adjusted loss of 26 cents per share. The mean expectation of seven analysts was for a loss of 31 cents. Reported revenue was zero; analysts expected zero. Shares had risen by 9.7% this quarter.
Reuters · 03/28 21:02
Recap: Achieve Life Sciences Q4 Earnings
Achieve Life Sciences reported its Q4 earnings on March 28. The company beat estimates by 16.0%. The company's revenue was down $0 from the same period last year. Achieve Life Sciences is expected to announce its earnings on April 28, 2024 at 4:01 p.m.
Benzinga · 03/28 20:15
Achieve Life Sciences Q4 EPS $(0.26) Beats $(0.31) Estimate
Benzinga · 03/28 20:14
Achieve Life Sciences GAAP EPS of -$0.26 beats by $0.05
Q4 GAAP EPS of -$0.26 beats by $0.05. As of December 31, 2023, the Company’s cash, cash equivalents, and restricted cash was $15.6 million. Achieve Life Sciences, Inc. (ACHV) stock.
Seeking Alpha · 03/28 20:04
More
Webull provides a variety of real-time ACHV stock news. You can receive the latest news about Achieve Life Sciences Inc through multiple platforms. This information may help you make smarter investment decisions.
About ACHV
Achieve Life Sciences, Inc. is a late-stage clinical pharmaceutical company. The Company is engaged in development and commercialization of cytisinicline for smoking cessation and nicotine addiction. The Company’s product candidate, cytisinicline, is a naturally occurring, plant-based alkaloid. Cytisinicline is structurally similar to nicotine and has a well-defined, dual-acting mechanism of action that is both agonistic and antagonistic. Cytisinicline is a partial agonist that binds with high affinity to the alpha-4 beta-2, nicotinic acetylcholine receptors in the brain. Through its dual-acting partial agonist/partial antagonist activity, cytisinicline helps reduce nicotine cravings, withdrawal symptoms and reward and satisfaction associated with smoking. It is developing cytisinicline as an aid to smoking cessation and treatment for nicotine addiction to address the limitations of both prescription drugs and of over the counter (OTC) products.